Nanjing Jiqun Biotechnology

Nanjing Jiqun Biotechnology is a biopharmaceutical company based in Nanjing, China, specializing in the development of exosome-based drug delivery systems and RNA therapeutics. Founded in 2020 by Dr. Chen-Yu Zhang, a leading expert in extracellular RNA from Nanjing University, the company leverages its proprietary Exo-Delivery platform to engineer exosomes for the targeted delivery of nucleic acid cargoes. Their technology addresses the critical challenge of delivering siRNA, miRNA, and mRNA to specific tissues, aiming to treat previously undruggable diseases. The company's pipeline focuses on high-impact areas such as oncology, metabolic disorders, and infectious diseases. By utilizing naturally occurring exosomes, Jiqun Biotech aims to provide therapies with lower immunogenicity and higher stability compared to synthetic lipid nanoparticles. The company is currently in the pre-clinical stage, advancing several candidates toward IND-enabling studies.